Moonwalk Biosciences, Inc. — SEC Form D Filing

Moonwalk Biosciences, Inc. filed an SEC Form D on September 14, 2026, reporting $60.00M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
September 14, 2026
Amount reported
$60.00M
Round stage
Series B+
Industry
Biotechnology
Website
https://moonwalk.bio/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Current obesity treatments, while effective, still have unmet needs such as gastrointestinal side effects, loss of lean mass, weight regain upon discontinuation, and a need for frequent dosing. These issues limit their effectiveness and patient tolerability.

Solution

Moonwalk Biosciences is developing first-in-class, adipose-targeted RNA therapies. These therapies aim to address the biology of cardiometabolic diseases and obesity through non-appetite suppressing mechanisms, designed to preserve lean muscle, improve tolerability, and allow for infrequent dosing.

Why now

Advances in AI-enabled drug discovery, human genetics, epigenetics, and RNA therapy technology enable the development of novel, targeted treatments for complex diseases like obesity, addressing the limitations of current therapies.

Verdict

Investors backed Moonwalk Biosciences on the promise of RNA therapeutics directly addressing obesity's biological underpinnings, bypassing the limitations of current appetite-suppressing agents. This cleared because of the perceived opportunity to create a more durable, targeted, and tolerable solution for a massive market, not because of immediate de-risked clinical data. The implicit bet was on Moonwalk's ability to successfully translate adipose-targeted RNA mechanisms into a superior clinical profile, which simultaneously limited upside by tying success to a long, capital-intensive development cycle and the eventual competitive landscape.

Source: SEC EDGAR Form D filing